Isabella Romano

Dr. Isabella Romano

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2023 in Vaccine
Verified
Journal Article
Closed access
IRIsabella Romano
Isabella Romano
SCSusan B. Core
Susan B. Core
NLNaomi R. Lee
Naomi R. Lee
CMCurtis Mowry
Curtis Mowry
KRKoen K.A. Van Rompay
Koen K.A. Van Rompay
KFKathryn Frietze
Kathryn Frietze

3 August 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
AJAndzoa N Jamus
Andzoa N Jamus
ZWZoe Elizabeth-Rifon Wilton
Zoe Elizabeth-Rifon Wilton
SASamantha D. Armijo
Samantha D. Armijo
JFJulian Flanagan
Julian Flanagan
IRIsabella Romano
Isabella Romano
KFKathryn Frietze
Kathryn Frietze
Background/Objectives: Intramuscular immunization elicits systemic IgG and is the primary route of vaccine administration in humans. However, there is growing interest in utilizing other routes of administration to tailor antibody profiles, increase immunity at primary sites of infection, simplify administration, and eliminate needle waste. Here, we investigated the antibody profiles elicited by immunization with bacteriophage virus-like particle vaccine platforms at various routes of administration. Methods: We chose two model bacteriophage vaccines for investigation: bacteriophage MS2 virus-like particles (VLPs) recombinantly displaying a short, conserved peptide from Chlamydia trachomatis major outer membrane protein (MS2) and bacteriophage Qβ VLPs displaying oxycodone through chemical conjugation (Qβ). We comprehensively characterized the antibodies elicited systemically and at various mucosal sites when the vaccines were administered intramuscularly, intranasally or periocularly with or without an intramuscular prime using various prime/boost schemes. Results: Intranasal and periocular immunization elicited robust mucosal and systemic IgA responses for both MS2 and Qβ. The intramuscular prime followed by intranasal or periocular boosts elicited broad antibody responses, and increased antibodies titers at certain anatomical sites. Conclusions: These findings demonstrate the tractability of bacteriophage VLP-based vaccines in generating specific antibody profiles based on the prime–boost regimen and route of administration.

29 August 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
IRIsabella Romano
Isabella Romano
BJBrandi Johnson-Weaver
Brandi Johnson-Weaver
SCSusan B. Core
Susan B. Core
AJAndzoa N Jamus
Andzoa N Jamus
MBMarcus Brackeen
Marcus Brackeen
KFKathryn Frietze
Kathryn Frietze
Opioid overdoses and the growing rate of opioid use disorder (OUD) are major public health concerns, particularly in the United States. Current treatment approaches for OUD have failed to slow the growth of the opioid crisis. Opioid vaccines have shown pre-clinical success in targeting multiple different opioid drugs. However, the need for many immunizations can limit their clinical implementation. In this study, we investigate the development of novel opioid vaccines by independently targeting fentanyl and the active metabolites of heroin using a bacteriophage virus-like particle (VLP) vaccine platform. We establish the successful conjugation of haptens to bacteriophage Qβ VLPs and demonstrate immunogenicity of Qβ-fentanyl, Qβ-morphine, and Qβ-6-acetylmorphine in animal models after one or two immunizations. We show that in independently or in combination, these vaccines elicit high-titer, high-avidity, and durable antibody responses. Moreover, we reveal their protective capacities against heroin or fentanyl challenge after two immunizations. Overall, these findings establish Qβ-VLP conjugated vaccines for heroin and fentanyl as very promising opioid vaccine candidates.

1 September 2026
Verified
Report
Closed access
A(Albuquerque Sandia National Laboratories (Snl-Nm)
Albuquerque Sandia National Laboratories (Snl-Nm)
JCJesse Cahill
Jesse Cahill
U(Usdoe National Nuclear Security Administration (Nnsa)
Usdoe National Nuclear Security Administration (Nnsa)
JAJack Arnold
Jack Arnold
IRIsabella Romano
Isabella Romano
JSJoseph Schoeniger
Joseph Schoeniger